AZD1402

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Asthma

Phase 1

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

CompletedNCT03921268

AstraZenecaAsthma

Start: 2019-03-25End: 2019-06-13Updated: 2019-06-21

Phase 2

Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids

TerminatedNCT04643158

AstraZenecaAsthma

Start: 2021-03-12End: 2023-07-20Updated: 2025-08-28

Related Papers

Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)

Respiratory Research2026-04-14